SLS Key Statistics, Chart & Performance
The current stock price of SLS is 3.46 USD. In the past month the price increased by 76.53%. In the past year, price increased by 263.26%.
SLS Latest News, Press Relases and Analysis
SLS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About SLS
Company Profile
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. The company is headquartered in New York City, New York and currently employs 15 full-time employees. The company went IPO on 2008-03-12. The firm is focused on the development of therapeutics for a range of cancer indications. The firm's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The firm is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
Company Info
SELLAS LIFE SCIENCES GROUP I
7 Times Square, Suite 2503
New York City NEW YORK 10018 US
CEO: Angelos M. Stergiou
Employees: 15
Phone: 16462005278
SELLAS LIFE SCIENCES GROUP I / SLS FAQ
What does SLS do?
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. The company is headquartered in New York City, New York and currently employs 15 full-time employees. The company went IPO on 2008-03-12. The firm is focused on the development of therapeutics for a range of cancer indications. The firm's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The firm is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
Can you provide the latest stock price for SELLAS LIFE SCIENCES GROUP I?
The current stock price of SLS is 3.46 USD. The price decreased by -10.36% in the last trading session.
Does SELLAS LIFE SCIENCES GROUP I pay dividends?
SLS does not pay a dividend.
What is the ChartMill technical and fundamental rating of SLS stock?
SLS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting SLS stock to perform?
7 analysts have analysed SLS and the average price target is 6.97 USD. This implies a price increase of 101.44% is expected in the next year compared to the current price of 3.46.
How is the valuation of SELLAS LIFE SCIENCES GROUP I (SLS) based on its PE ratio?
SELLAS LIFE SCIENCES GROUP I (SLS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.28).
Should I buy SLS stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SLS.
SLS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to SLS. When comparing the yearly performance of all stocks, SLS is one of the better performing stocks in the market, outperforming 98.73% of all stocks.
SLS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SLS. SLS has a great financial health rating, but its profitability evaluates not so good.
SLS Financial Highlights
Over the last trailing twelve months SLS reported a non-GAAP Earnings per Share(EPS) of -0.28. The EPS increased by 59.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.32% | ||
| ROE | -56.85% | ||
| Debt/Equity | 0 |
SLS Forecast & Estimates
7 analysts have analysed SLS and the average price target is 6.97 USD. This implies a price increase of 101.44% is expected in the next year compared to the current price of 3.46.